AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23737536 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarter-dose DSA program
Number of subjects: 20
Study 20031260 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspherical AcriSmart 36A IOL
Number of subjects: 25
Study 20031260 — intervention group
Group type: COMPARATOR
Intervention: Zero-aberration AcriSmart 46LC IOL
Number of subjects: 25
Study 20031260 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole population
Number of subjects: 25
Study 18701205 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing 2.5x10(9)CFU of L. rhamnosus GR‐1 and L. reuteri RC‐14
Number of subjects: 72
Study 18701205 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 72
Study 17043419 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (0.5 microg/kg/min)
Number of subjects: 50
Study 17043419 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 50
Study 14583409 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative image training
Number of subjects: 0
Study 14583409 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 0
Study 10999778 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg calcium daily
Number of subjects: 438
Study 10999778 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg 25OH vitamin D3 daily
Number of subjects: 438
Study 10999778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study 8668669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 3% gel applied to the back
Number of subjects: 24
Study 8668669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 3% gel applied to the arm
Number of subjects: 24
Study 8668669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 3% gel applied to the knee
Number of subjects: 24
Study 8668669 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen solution (60 mg/ml) applied to the back (reference treatment)
Number of subjects: 24
Study 8155449 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial ventilation with isoflurane and nitrous oxide in oxygen and atracurium (group A)
Number of subjects: 50
Study 8155449 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventilation with isoflurane and nitrous oxide in oxygen (group B)
Number of subjects: 50
Study 3048225 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg scopolamine hydrobromide
Number of subjects: 9
Study 3048225 — intervention group
Group type: COMPARATOR
Intervention: 1 mg oral lorazepam
Number of subjects: 9
Study 3048225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3048225 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg scopolamine hydrobromide
Number of subjects: 9
Study 3048225 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg scopolamine hydrobromide
Number of subjects: 9
Study 29178617 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2584702
Number of subjects: 0
Study 29178617 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2584702 with atorvastatin
Number of subjects: 0
Study 28391397 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-lifting after 12 months
Number of subjects: 141
Study 28391397 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 141
Study 27754567 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus plus mycophenolate mofetil (Arm 1)
Number of subjects: 569
Study 27754567 — intervention group
Group type: COMPARATOR
Intervention: Prolonged-release tacrolimus plus sirolimus (Arm 2)
Number of subjects: 569
Study 24101696 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl‐L‐carnitine (52-week trial)
Number of subjects: 424
Study 24101696 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c at baseline
Number of subjects: 424
Study 24101696 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine classifier using HbA1c
Number of subjects: 424
Study 21192237 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04494700 10 mg (after a 6-day loading dose of 30 mg/d)
Number of subjects: 67
Study 21192237 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04494700 20 mg (after a loading dose of 60 mg/d)
Number of subjects: 67
Study 21192237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 21192237 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04494700 (both doses)
Number of subjects: 67
Study 19179904 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter duration of platinum-based therapy (3-4 cycles)
Number of subjects: 0
Study 19179904 — intervention group
Group type: COMPARATOR
Intervention: Longer duration of platinum-based therapy
Number of subjects: 0
Study 19179904 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier use of second-line therapy after completion of four cycles of platinum-based therapy
Number of subjects: 0
Study 19179904 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment paradigm of initiating second-line therapy upon disease progression
Number of subjects: 0
Study 19179904 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of targeted agents (bevacizumab or cetuximab) to initial chemotherapy
Number of subjects: 0
Study 19179904 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with targeted agents
Number of subjects: 0
Study 17355018 — intervention group
Group type: EXPERIMENTAL
Intervention: PRESTIGE ST Cervical Disc System (arthroplasty)
Number of subjects: 541
Study 17355018 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 541
Study 15127155 — intervention group
Group type: EXPERIMENTAL
Intervention: Linac radiosurgery (median dose 20 Gy)
Number of subjects: 117
Study 15127155 — intervention group
Group type: EXPERIMENTAL
Intervention: Linac radiosurgery
Number of subjects: 117
Study 15127155 — intervention group
Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 117
Study 11520646 — intervention group
Group type: EXPERIMENTAL
Intervention: Very rapid enrollment
Number of subjects: 28992
Study 11520646 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid enrollment
Number of subjects: 28992
Study 11520646 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate enrollment
Number of subjects: 28992
Study 11520646 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow enrollment
Number of subjects: 28992
Study 11520646 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial rate of accrual
Number of subjects: 28992
Study 11520646 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment during the first month or two
Number of subjects: 28992
Study 9924567 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Number of subjects: 74
Study 9924567 — intervention group
Group type: COMPARATOR
Intervention: Incubator care
Number of subjects: 74
Study 8576531 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeler Pulsair 2000
Number of subjects: 31
Study 8576531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomey Pro‐Ton
Number of subjects: 31
Study 8576531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono‐Pen XL
Number of subjects: 31
Study 8576531 — intervention group
Group type: EXPERIMENTAL
Intervention: Perkins
Number of subjects: 31
Study 8576531 — intervention group
Group type: EXPERIMENTAL
Intervention: Schiotz
Number of subjects: 31
Study 8576531 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 31
Study 2368961 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (3.75 mg/ml for 8 min)
Number of subjects: 8
Study 2368961 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 2368961 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide
Number of subjects: 8
Study 351664 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Training
Number of subjects: 0
Study 351664 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Relaxation plus Assertive Training
Number of subjects: 0
Study 351664 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Training
Number of subjects: 0
Study 351664 — intervention group
Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 0
Study 351664 — intervention group
Group type: COMPARATOR
Intervention: Medication and leaderless group
Number of subjects: 0
Study 30149204 — intervention group
Group type: EXPERIMENTAL
Intervention: Dieting prime
Number of subjects: 225
Study 30149204 — intervention group
Group type: COMPARATOR
Intervention: Neutral prime
Number of subjects: 225
Study 28925059 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine 5% nail lacquer (once-weekly application)
Number of subjects: 0
Study 28925059 — intervention group
Group type: COMPARATOR
Intervention: Ciclopirox 8% nail lacquer (once-daily application)
Number of subjects: 0
Study 28925059 — intervention group
Group type: COMPARATOR
Intervention: Urea 40% ointment/bifonazole 1% cream combination (once-daily application)
Number of subjects: 0
Study 28925059 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine 5% nail lacquer
Number of subjects: 0
Study 28925059 — intervention group
Group type: COMPARATOR
Intervention: Urea 40% ointment
Number of subjects: 0
Study 28925059 — intervention group
Group type: COMPARATOR
Intervention: Bifonazole 1% cream
Number of subjects: 0
Study 25456892 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated health management model
Number of subjects: 100
Study 25456892 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 22882570 — intervention group
Group type: EXPERIMENTAL
Intervention: One-lung ventilation (OLV)
Number of subjects: 30
Study 22882570 — intervention group
Group type: COMPARATOR
Intervention: Two-lung ventilation (TLV)
Number of subjects: 30
Study 21997779 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan(®) cervical disc prosthesis
Number of subjects: 83
Study 21997779 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 83
Study 18294021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular risperidone, 25 mg every other week
Number of subjects: 31
Study 18294021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 18294021 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (risperidone and placebo)
Number of subjects: 31
Study 16579924 — intervention group
Group type: COMPARATOR
Intervention: Fulguration with ball electrode
Number of subjects: 100
Study 16579924 — intervention group
Group type: EXPERIMENTAL
Intervention: Monsel's paste
Number of subjects: 100
Study 12686367 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa and bulimia nervosa subjects (271 total)
Number of subjects: 271
Study 12686367 — intervention group
Group type: COMPARATOR
Intervention: Matched normal control group (271 total)
Number of subjects: 271
Study 10924665 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT with low-dose stimulus intensity (just above seizure threshold)
Number of subjects: 62
Study 10924665 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT with two-fold stimulus intensity
Number of subjects: 62
Study 10924665 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT with four-fold stimulus intensity
Number of subjects: 62
Study 10924665 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT (all dosage groups)
Number of subjects: 62
Study 1954636 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA) 12 mg/m2 daily for 3 days + Cytosine arabinoside 200 mg/m2 daily for 5 days
Number of subjects: 120
Study 1954636 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin (DNR) 50 mg/m2 daily for 3 days + Cytosine arabinoside 200 mg/m2 daily for 5 days
Number of subjects: 120
Study 6908875 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term gestagen therapy (100 mg medrogestone or medroxyprogesterone acetate daily for 2-5 years)
Number of subjects: 124
Study 31790979 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute abstinence
Number of subjects: 0
Study 31790979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 0
Study 31790979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30479087 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-based hyperthermic intraperitoneal chemotherapy (HIPEC) with 175 mg/m² for 90 minutes after interval debulking surgery (IDS)
Number of subjects: 65
Study 30479087 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval debulking surgery (IDS) followed by HIPEC
Number of subjects: 65
Study 29262749 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally focused exercise
Number of subjects: 47
Study 29262749 — intervention group
Group type: EXPERIMENTAL
Intervention: Internally focused exercise
Number of subjects: 47
Study 29262749 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 participants)
Number of subjects: 47
Study 29262749 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise groups (External and Internal)
Number of subjects: 47
Study 26162889 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel NIPPV
Number of subjects: 456
Study 26162889 — intervention group
Group type: COMPARATOR
Intervention: CMV NIPPV
Number of subjects: 456
Study 24882554 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50mg daily (4 weeks on, 2 weeks off)
Number of subjects: 34
Study 23073596 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine porous bone mineral (BPBM) containing bone morphogenetic proteins (BMP)
Number of subjects: 9
Study 23073596 — intervention group
Group type: COMPARATOR
Intervention: Bovine porous bone mineral (BPBM) alone
Number of subjects: 9
Study 19915083 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ppm HFC-245fa
Number of subjects: 10
Study 19915083 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ppm HFC-245fa
Number of subjects: 10
Study 19915083 — intervention group
Group type: COMPARATOR
Intervention: Control (0 ppm HFC-245fa)
Number of subjects: 10
Study 16500662 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg
Number of subjects: 47
Study 16500662 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Simvastatin 20mg and Losartan 100mg)
Number of subjects: 47
Study 16500662 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100mg
Number of subjects: 47
Study 15599947 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention (usual care plus family intervention); 5 sessions addressing family involvement, optimistic attitude, coping effectiveness, uncertainty reduction, and symptom management
Number of subjects: 134
Study 15599947 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention (usual care plus family intervention)
Number of subjects: 134
Study 15599947 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 134
Study 12081828 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary chromium supplementation
Number of subjects: 618
Study 9925869 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogen clamp with DPNB
Number of subjects: 48
Study 9925869 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogen clamp without DPNB
Number of subjects: 48
Study 9925869 — intervention group
Group type: EXPERIMENTAL
Intervention: Gomco clamp with DPNB
Number of subjects: 48
Study 9925869 — intervention group
Group type: EXPERIMENTAL
Intervention: Gomco clamp without DPNB
Number of subjects: 48
Study 9925869 — intervention group
Group type: EXPERIMENTAL
Intervention: DPNB
Number of subjects: 48
Study 9925869 — intervention group
Group type: COMPARATOR
Intervention: No DPNB
Number of subjects: 48
Study 7496451 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning by an oscillating bed
Number of subjects: 103
Study 7496451 — intervention group
Group type: COMPARATOR
Intervention: Standard 2-hour turning
Number of subjects: 103
Study 2215826 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (415 pmol i.v. bolus followed by a 90‐min infusion, total dose 62.25 pmol.kg‐1)
Number of subjects: 6
Study 2215826 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 6
Study 2215826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6298156 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed beam radiation therapy (neutron treatment)
Number of subjects: 2500
Study 6298156 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron treatment
Number of subjects: 2500
Study 6298156 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative mixed beam irradiation
Number of subjects: 2500
Study 6298156 — intervention group
Group type: COMPARATOR
Intervention: Mixed beam irradiation alone
Number of subjects: 2500
Study 31421426 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) therapy
Number of subjects: 36
Study 31421426 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LMWH therapy)
Number of subjects: 36
Study 30160050 — intervention group
Group type: EXPERIMENTAL
Intervention: Brody score cut-off of 3.6 in PEIT for ≥0.3 annual pulmonary exacerbations
Number of subjects: 141
Study 30160050 — intervention group
Group type: EXPERIMENTAL
Intervention: Brody score cut-off of 2.1 in WI RCT for ≥0.3 annual pulmonary exacerbations
Number of subjects: 141
Study 30160050 — intervention group
Group type: EXPERIMENTAL
Intervention: Brody CT score
Number of subjects: 141
Study 30160050 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1 % predicted
Number of subjects: 141
Study 26986096 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR-based triple therapy (60 mg once daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily)
Number of subjects: 177
Study 26986096 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole-based triple therapy (20 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily)
Number of subjects: 177
Study 26986096 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR-based triple therapy
Number of subjects: 177
Study 26986096 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole-based triple therapy
Number of subjects: 177
Study 25201463 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg + H2 group
Number of subjects: 450
Study 25201463 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg group
Number of subjects: 450
Study 25201463 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 450
Study 22534403 — intervention group
Group type: EXPERIMENTAL
Intervention: High progesterone group (mid-luteal phase)
Number of subjects: 56
Study 22534403 — intervention group
Group type: COMPARATOR
Intervention: Low progesterone group (non-luteal phases)
Number of subjects: 56
Study 20447229 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug dependence treatment trials
Number of subjects: 98
Study 20447229 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials comparing widely different treatments
Number of subjects: 98
Study 20447229 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiments with large samples
Number of subjects: 98
Study 18490084 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with apnea who participated in the vaccine trial
Number of subjects: 175
Study 18490084 — intervention group
Group type: COMPARATOR
Intervention: Very low birth weight (VLBW) infants control group
Number of subjects: 175
Study 18490084 — intervention group
Group type: COMPARATOR
Intervention: Infants from the vaccine trial control group
Number of subjects: 175
Study 15689431 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 30059
Study 15689431 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 30059
Study 12585782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Systematic walking program for 12 weeks
Number of subjects: 52
Study 12585782 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No walking program
Number of subjects: 52
Study 12585782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Systematic walking program
Number of subjects: 52
Study 10507206 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma irradiation (25.2 kGy)
Number of subjects: 21
Study 10507206 — intervention group
Group type: COMPARATOR
Intervention: Control (water at 20 degrees C for 12 days)
Number of subjects: 21
Study 10507206 — intervention group
Group type: EXPERIMENTAL
Intervention: Freezing (-18 degrees C for 12 days)
Number of subjects: 21
Study 7571769 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (2 x 40 mg)
Number of subjects: 24
Study 7571769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (2 x 10 mg)
Number of subjects: 24
Study 1943183 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Wisconsin solution (UW)
Number of subjects: 29
Study 1943183 — intervention group
Group type: COMPARATOR
Intervention: Stanford solution
Number of subjects: 29
Study 6168198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric suction
Number of subjects: 21
Study 6168198 — intervention group
Group type: COMPARATOR
Intervention: Nothing by mouth (control)
Number of subjects: 21
Study 31755037 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (54 cases)
Number of subjects: 72
Study 31755037 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 cases)
Number of subjects: 72
Study 30687986 — intervention group
Group type: EXPERIMENTAL
Intervention: StudiCare SAD (unguided internet-based self-help intervention)
Number of subjects: 200
Study 30687986 — intervention group
Group type: EXPERIMENTAL
Intervention: StudiCare SAD
Number of subjects: 200
Study 30687986 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (WLC) with full access to treatment as usual
Number of subjects: 200
Study 28500516 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo gel)
Number of subjects: 8
Study 28500516 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA + laser
Number of subjects: 8
Study 28500516 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser (Nd:YAG)
Number of subjects: 8
Study 28500516 — intervention group
Group type: EXPERIMENTAL
Intervention: F + Sn + E + laser
Number of subjects: 8
Study 28500516 — intervention group
Group type: EXPERIMENTAL
Intervention: F + E + laser
Number of subjects: 8
Study 28500516 — intervention group
Group type: EXPERIMENTAL
Intervention: F
Number of subjects: 8